LRRK2 and Parkinson disease: To extend our findings to a wider range of disease stages, we further examined CSF samples obtained from subjects with LRRK2 mutations (which lead to late-onset PD similar to the idiopathic disease), including patients at preclinical stages [18,19], and results published previously [17,20] from a large multi-center collaborative cohort including subjects with later stage PD.